Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 7/20 | 0.47 |
| ▸ | PDE4A | P27815 | 6/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | STAT6 | P42226 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234639 | 0.86 | MAPT (0.55) | LMNAMAPTADORA3HTTGAA | |
| SCHEMBL3237069 | 0.85 | LMNA (0.51) | LMNAMAPTADORA3HTTGAA | |
| SCHEMBL3238173 | 0.84 | MAPT (0.55) | LMNAMAPTADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL3233622 | 0.83 | HTT (0.49) | LMNAMAPTADORA3HTTGAA | |
| SCHEMBL3234215 | 0.83 | HTT (0.49) | LMNAMAPTADORA3HTTGAA | |
| SCHEMBL13940720 | 0.82 | MAPT (0.51) | LMNAMAPTADORA3HTTGAA | |
| SCHEMBL3229109 | 0.82 | ADORA2A (0.59) | LMNAMAPTADORA3HTTALDH1A1 | |
| SCHEMBL3233596 | 0.81 | MAPT (0.48) | LMNAMAPTADORA3SMN1; SMN2ALDH1A1 | |
| SCHEMBL3236349 | 0.81 | MAPT (0.50) | LMNAMAPTADORA3HTTGAA | |
| SCHEMBL3240004 | 0.81 | MAPT (0.56) | LMNAMAPTADORA3HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | claimed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | claimed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | claimed |
| US-20100273835-A1 | NOVEL COMPOUNDS | PROBIODRUG AG (DE) | 2010-10-28 | — | — | US | disclosed |
| EP-2178830-A2 | NOVEL COMPOUNDS | Probiodrug AG (DE) | 2010-04-28 | — | — | EP | disclosed |
| EP-2146996-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | AstraZeneca AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023704-A1 | Novel Compounds 737 | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| WO-2009007415-A2 | NOVEL COMPOUNDS | PROBIODRUG AG (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130314-A1 | XANTHINE COMPOUNDS HAVING A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATOR EFFECT | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273835-A1 | NOVEL COMPOUNDS | IL6, PREP, PEPD | LMNA 3190/4885MAPT 206/4885ADORA3 2024/4885 |
| US-20090023704-A1 | Novel Compounds 737 | GRPR, GABRB1, GABBR1 | LMNA 3908/4885MAPT 2910/4885ADORA3 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.